# Rinvoq

NDC: 0074-2310
Generic name: Upadacitinib
Labeler / Manufacturer: AbbVie Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, EXTENDED RELEASE
Routes: ORAL
Marketing started: 20190816

FDA application: NDA211675

## Active ingredients

- UPADACITINIB: 30 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0074-2310"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0074-2310
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095